Niagen Bioscience, Inc.

Hello everyone. Thank you for joining us and welcome to the Niagen Bioscience second quarter 2026 earnings conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Lauren Borzanski, Assistant Controller. Please go ahead.

Good afternoon and welcome to Niagen Bioscience, Inc.'s second quarter 2026 conference call. Joining me today are our Chief Executive Officer Rob Fried, Chief Financial Officer Ozan Pamir, and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao. Dr. Shao will join the call for Q&A. Before we begin, I'd like to remind everyone that today's call may include forward-looking statements. These statements relate to, among other things, our research and development activities, clinical trial plans and timing, regulatory filings, expansion into new markets, business development opportunities, and our expected financial and operating performance. These statements are based on our current expectations as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For our discussion of these risks, please refer to our most recent Form 10Q, and other filings with the SEC. We undertake no obligation to update these statements except as required by law. In addition, we may reference certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures can be found in today's earnings release and presentation, both available in the investor relations section of our website. With that, it's now my pleasure to turn the call over to our Chief Executive Officer, Rob Fried.

Thank you, Lauren, and good afternoon, everyone, and thank you for joining us today. This quarter marks another important milestone in the evolution of Niagen Bioscience. For many years, investors knew us primarily as the company behind TruNiagen, the leading nicotinamide riboside NAD supplement. Today, we are becoming something much broader, a science-driven platform company built around the biology of NAD. with opportunities spanning consumer health, injectable and IV, skincare, and pharmaceuticals. Our name, Niagen Bioscience, reflects that evolution. It represents the company we are building and the opportunity we believe lies ahead. As we look at the progress we've made in 2026 in developing our platform, we see this year as our springboard for growth and for value creation. Our financial results this quarter demonstrate the resilience of our core business, while our strategic progress reinforces our confidence that we're building multiple long-term engines of growth. Today, Niagen Bioscience spans consumer supplements, branded ingredients, intravenous delivery through Niagen Plus, skin care, and pharmaceutical development. These businesses are connected by a common scientific foundation and increasingly reinforce one another. The scientific discoveries guide our commercial path and the commercial adoption expands awareness of Niagen. Pharmaceutical development deepens our understanding of NAD biology while expanding the long term value of our intellectual property. That integrated platform is what differentiates Niagen Bioscience. Global interest in NAD continues to accelerate. We estimate the worldwide NAD supplement market now exceeds $2 billion annually, while the IV and injection market has now grown beyond $500 million. We believe these markets remain in the early stages of their development as scientific understanding of cellular NAD continues to expand. Looking forward, we believe additional opportunities in skincare, IV and injections, pharmaceuticals, and other healthcare applications have the potential to substantially expand the overall addressable market. For more than a decade, Niagen has helped define this category through scientific leadership, regulatory excellence, intellectual property, and what we believe is the industry's largest body of human clinical research supporting NAD and nicotinamide riboside. Those advantages continue to differentiate us as awareness of NAD grows around the world. Our core business continues to provide a solid foundation, and we expect our e-commerce business to continue to be the engine for consistent growth. During the quarter, TrueNight and website sales increased 23% year over year, while Amazon sales increased 10%. We estimate Amazon growth would have been approximately 19% absent a temporary platform issue during early June that has since been resolved. Within the ingredient business, purchases from Life Extension were lower than last year, affecting quarterly comparisons. We also continue to see competitive activity from NMN and NAD as a straight ingredient in certain channels. While we recognize these near-term challenges, our confidence remains grounded in our scientific leadership, intellectual property, regulatory position, manufacturing quality, and extensive body of clinical evidence supporting Niagen. Across every market in which we participate, we are seeing the same trend emerge. Organizations seeking the most scientifically validated approach to elevating NAD are increasingly choosing Niagen.